Wird geladen...
Fenofibrate, HDL, and Cardiovascular Disease in Type-2 Diabetes: The DAIS Trial
BACKGROUND: There are conflicting reports on the role of fibrates in CVD-risk. Several studies indicate beneficial effects of fibrates on CVD risk in type-2 diabetic patients. We tested how fenofibrate changes lipoprotein subfractions and glucose homeostasis in type-2 diabetic patients. STUDY DESIGN...
Gespeichert in:
| Veröffentlicht in: | Atherosclerosis |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4808361/ https://ncbi.nlm.nih.gov/pubmed/26854974 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.atherosclerosis.2016.01.028 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|